Page last updated: 2024-10-27

fluorouracil and Breast Cancer, Male

fluorouracil has been researched along with Breast Cancer, Male in 43 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib."9.19Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014)
"We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)."9.16Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012)
"To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer."9.14First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010)
" Patients with breast cancer scheduled to receive FAC chemotherapy (5-fluorouracil, adriamycin and cyclophosphamide) were eligible for the study."9.09A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. ( Griffin, T; Hidalgo, M; Medina, G; Rinaldi, D; Turner, J; Von Hoff, DD, 1999)
"The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer."9.09[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999)
"In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines."9.08Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997)
"Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities."7.91Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. ( Charlton, P; DeSouza, K; Kapiris, M; Karapanagiotou, E; Mansi, J; Marinaki, A; Okonta, L; Papadatos-Pastos, D; Pouptsis, A; Stavraka, C, 2019)
" The present study, therefore, aimed at measuring interstitial tumor 5-fluorouracil (5-FU) pharmacokinetics and 5-FU transfer rates from plasma into the tumor interstitium in breast cancer patients."7.695-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. ( Blochl-Daum, B; Eichler, HG; Gnant, M; Helbich, T; Jakesz, R; Jansen, B; Mader, RM; Müller, M; Steger, GG; Steiner, B, 1997)
"Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib."5.19Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014)
"We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)."5.16Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012)
"This phase II study in breast cancer patients assessed the utility of a single 6 mg subcutaneous dose of pegfilgrastim administered on day 9 of an intravenous (IV) "split" CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2) and 5-fluorouracil 600 mg/m(2)) chemotherapy regimen administered on days 1 and 8 and repeated every 28 days for 6 cycles."5.14Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. ( Bacon, P; Casas, A; Castellanos, J; Duque, A; Falcone, A; Gridelli, C; Lawrinson, S; Mansutti, M; Mattioli, R; Skacel, T, 2009)
"To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer."5.14First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010)
" Patients with breast cancer scheduled to receive FAC chemotherapy (5-fluorouracil, adriamycin and cyclophosphamide) were eligible for the study."5.09A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. ( Griffin, T; Hidalgo, M; Medina, G; Rinaldi, D; Turner, J; Von Hoff, DD, 1999)
"The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer."5.09[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999)
"Thirty-two patients undergoing adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or doxorubicin-CMF for stages I to II breast cancer were included after having chemotherapy delays due to neutropenia (absolute neutrophil count [ANC] < 1."5.08Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. ( Albanell, J; Baselga, J; Bellmunt, J; Bermejo, B; Carulla, J; Eres, N; Gallardo, E; Ribas, A; Solé-Calvo, LA; Vera, R; Vidal, R, 1996)
"In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines."5.08Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997)
"Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities."3.91Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. ( Charlton, P; DeSouza, K; Kapiris, M; Karapanagiotou, E; Mansi, J; Marinaki, A; Okonta, L; Papadatos-Pastos, D; Pouptsis, A; Stavraka, C, 2019)
" Also, as the veins in the lower extremity were filled with thrombus, we gave him an anticoagulant (Edoxaban), but due to the malignant hyper coagulable state (Trousseau syndrome) a CV port could not be implanted."3.91[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome]. ( Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K, 2019)
"The subjects of this study were 45 patients with locally advanced breast cancer (LABC), who received the cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) regimen as NACT."3.77Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. ( Agrawal, D; Bajpai, P; Chandra, R; Mehrotra, PK; Mishra, A, 2011)
"We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy."3.74Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007)
" The present study, therefore, aimed at measuring interstitial tumor 5-fluorouracil (5-FU) pharmacokinetics and 5-FU transfer rates from plasma into the tumor interstitium in breast cancer patients."3.695-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. ( Blochl-Daum, B; Eichler, HG; Gnant, M; Helbich, T; Jakesz, R; Jansen, B; Mader, RM; Müller, M; Steger, GG; Steiner, B, 1997)
"Patients with early breast cancer surgically treated and eligible to adjuvant chemotherapy were enrolled."2.76Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. ( Albrile, F; Biggi, A; Bobbio, M; Feola, M; Francini, A; Garrone, O; Merlano, M; Occelli, M; Visconti, G, 2011)
"Patients with inflammatory breast cancer or more than nine ipsilateral lymph node involvement without evidence of distant metastasis were randomized to receive either standard dose 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) every 3 weeks for nine courses (control) or six courses of FAC followed by two courses of cyclophosphamide (5."2.69A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma. ( Aref, IM; Cross, PW; Gertler, SZ; Grimard, LJ; Hanson, J; Huan, SD; Malik, ST; St Cyr, DA; Stewart, DJ; Tomiak, EM; Verma, S; Yau, JC, 2000)
" Forty-five patients were evaluable for response (nine per dosing group)."2.68Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. ( Affronti, ML; Cartee, L; Gilbert, C; Hoke, JA; Hussein, AM; Moore, S; Petros, WP; Rosner, GL; Ross, M; Rubin, P, 1995)
"Male breast cancer is a rare disease and the incidence has increased over the past 25 years."2.44[Clinical research advancement on male breast cancer]. ( Guo, XT; Liu, WC; Xue, Y, 2007)
"The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown."1.39Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. ( Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P, 2013)
"Identifying breast cancer patients at high risk of developing cardiotoxicity after anthracycline therapy would be of value in guiding the use of these agents."1.39Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. ( Feola, M; Garrone, O; Lo Nigro, C; Merlano, M; Monteverde, M; Vivenza, D, 2013)
"Thromboembolism is a well recognised complication of systemic chemotherapy and cancer."1.37The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. ( Boleti, K; Darby, A; Nolan, L; Simmonds, P, 2011)
"Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute."1.34A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. ( Anderson, WF; Berman, AW; Lippman, ME; Steinberg, SM; Swain, SM; Vatas, U; Walshe, JM, 2007)
"Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes."1.34Male breast cancer with mandibular metastasis. A case report. ( Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S, 2007)
" In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events."1.33[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006)
"According to our data, breast cancer most frequently occurred in patients of 45-49 years old."1.33[Clinical analysis of resectable breast cancer: a report of 6 263 cases]. ( Fu, JH; Huang, ZF; Lin, P; Long, H; Rong, TH; Tang, J; Wang, SY; Wang, X; Yang, MT; Zeng, CG, 2005)
"Male breast cancer is very rare, especially inflammatory breast cancer, which is an aggressive, rapidly proliferating manifestation of primary breast carcinoma."1.33Inflammatory breast cancer in a male. ( Choueiri, MB; El Saghir, NS; El-Hajj, II; Otrock, ZK; Tawil, AN, 2005)
"The prevalence of male breast cancer increases with age, and the presentation occurs at an average age of approximately 60 years, 10 years older than in females with the disease."1.32[Male breast cancer]. ( Kuroi, K; Toi, M, 2003)
"A total of 6 breast cancer patients, 5 with local recurrent tumors on their anterior chest wall and 1 with far advanced primary breast tumor, underwent multimodal therapy in which cryosurgery was performed in combination with local injection of the non-specific immunopotentiator OK-432."1.31[Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer]. ( Honda, S; Kawaguchi, Y; Kimura, A; Kunieda, K; Matsui, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H, 2001)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (23.26)18.2507
2000's15 (34.88)29.6817
2010's18 (41.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stavraka, C1
Pouptsis, A1
Okonta, L1
DeSouza, K1
Charlton, P1
Kapiris, M1
Marinaki, A1
Karapanagiotou, E1
Papadatos-Pastos, D1
Mansi, J1
Tashima, Y1
Kusanagi, K1
Takeda, Y1
Yoshimatsu, K1
Ishida, T1
Shinohara, S1
Hirai, A1
Imanishi, N1
Ichiki, Y1
Tanaka, F1
Di Lauro, L1
Vici, P1
Del Medico, P1
Laudadio, L1
Tomao, S1
Giannarelli, D1
Pizzuti, L1
Sergi, D1
Barba, M1
Maugeri-Saccà, M1
Vivenza, D1
Feola, M2
Garrone, O2
Monteverde, M1
Merlano, M2
Lo Nigro, C1
Kaczmarek, K1
Wiącek, MP1
Sulewski, A1
Kubaszewski, Ł1
Kaczmarczyk, J1
Nowakowski, A1
Wei, L1
Liang, X1
Li, S1
Liu, J1
Cihan, YB1
Saura, C1
Garcia-Saenz, JA1
Xu, B1
Harb, W1
Moroose, R1
Pluard, T1
Cortés, J1
Kiger, C1
Germa, C1
Wang, K1
Martin, M2
Baselga, J2
Kim, SB1
Occelli, M1
Francini, A1
Biggi, A1
Visconti, G1
Albrile, F1
Bobbio, M1
Mattioli, R1
Gridelli, C1
Castellanos, J1
Duque, A1
Falcone, A1
Mansutti, M1
Bacon, P1
Lawrinson, S1
Skacel, T1
Casas, A1
Njiaju, UO1
Truica, CI1
Arowolo, OA1
Akinkuolie, AA1
Lawal, OO1
Alatise, OI1
Salako, AA1
Adisa, AO1
Buccimazza, I1
Kaufmann, M1
Maass, N1
Costa, SD1
Schneeweiss, A1
Loibl, S1
Sütterlin, MW1
Schrader, I1
Gerber, B1
Bauer, W1
Wiest, W1
Tomé, O1
Distelrath, A1
Hagen, V1
Kleine-Tebbe, A1
Ruckhaeberle, E1
Mehta, K1
von Minckwitz, G1
Nolan, L1
Darby, A1
Boleti, K1
Simmonds, P1
Mishra, A1
Chandra, R1
Mehrotra, PK1
Bajpai, P1
Agrawal, D1
Gonzalez-Perez, LM1
Infante-Cossio, P1
Crespo-Torres, S1
Sanchez-Gallego, F1
Makhson, A1
Gligorov, J1
Lichinitser, M1
Lluch, A1
Semiglazov, V1
Scotto, N2
Mitchell, L1
Tjulandin, S1
Blum, JL1
Barrios, CH1
Feldman, N1
Verma, S2
McKenna, EF1
Lee, LF1
Gralow, J1
Kuroi, K1
Toi, M1
Yang, MT1
Rong, TH1
Huang, ZF1
Zeng, CG1
Long, H1
Fu, JH1
Lin, P1
Wang, X2
Wang, SY1
Tang, J1
Choueiri, MB1
Otrock, ZK1
Tawil, AN1
El-Hajj, II1
El Saghir, NS1
Ohta, K1
Dohden, K1
Morishita, M1
Hayashi, H1
Hattori, M1
Hosokawa, O1
Morita, M1
Kaizaki, Y1
Kiya, T1
Walshe, JM1
Berman, AW1
Vatas, U1
Steinberg, SM1
Anderson, WF1
Lippman, ME1
Swain, SM1
Karakuzu, A1
Koc, M1
Ozdemir, S1
Fontana, S1
Ghilardi, R1
Barbaglio, A1
Amaddeo, P1
Faldi, F1
Pericotti, S1
Zabel-du Bois, A1
Milker-Zabel, S1
Wannenmacher, M1
Debus, J1
Eucker, J1
Kühnl, A1
Possinger, K1
Xue, Y1
Guo, XT1
Liu, WC1
McLean, SR1
Shousha, S1
Francis, N1
Lim, A1
Eccles, S1
Nathan, M1
Brock, CS1
Palmieri, C1
Cartee, L1
Petros, WP1
Rosner, GL1
Gilbert, C1
Moore, S1
Affronti, ML1
Hoke, JA1
Hussein, AM1
Ross, M1
Rubin, P1
Tanaka, Y1
Ohmori, Y1
Toki, T1
Okazaki, Y1
Ogoshi, S1
Ogawa, Y1
Ribas, A1
Albanell, J1
Bellmunt, J1
Solé-Calvo, LA1
Bermejo, B1
Gallardo, E1
Vidal, R1
Vera, R1
Eres, N1
Carulla, J1
Müller, M1
Mader, RM1
Steiner, B1
Steger, GG1
Jansen, B1
Gnant, M1
Helbich, T1
Jakesz, R1
Eichler, HG1
Blochl-Daum, B1
Cakmakli, S1
Ersöz, S1
Tuğ, T1
Karaayvaz, M1
Akgül, H1
Bascioni, R1
Giorgi, F1
Silva, RR1
Acito, L1
Giustini, L1
De Signoribus, G1
Giuliodori, L1
Testa, E1
Cantore, M1
Fiorentini, G1
Cavazzini, G1
Molani, L1
Morandi, C1
Caforio, M1
Caleffi, G1
Mambrini, A1
Zamagni, D1
Smerieri, F1
Hidalgo, M1
Rinaldi, D1
Medina, G1
Griffin, T1
Turner, J1
Von Hoff, DD1
Taguchi, T1
Tsukamoto, F1
Watanabe, T1
Yoneda, K1
Takamura, Y1
Hojo, S1
Shiba, E1
Noguchi, S1
Davidson, NG1
Davis, AS1
Woods, J1
Snooks, S1
Cheverton, PD1
Yau, JC1
Gertler, SZ1
Hanson, J1
Grimard, LJ1
Malik, ST1
Aref, IM1
Cross, PW1
Tomiak, EM1
Stewart, DJ1
St Cyr, DA1
Huan, SD1
Takei, H1
Iino, Y1
Horiguchi, J1
Maemura, M1
Koibuchi, Y1
Yokoe, T1
Morishita, Y1
Jordan, VC1
Sugiyama, Y1
Saji, S1
Miya, K1
Kunieda, K1
Takao, H1
Kawaguchi, Y1
Kimura, A1
Honda, S1
Matsui, K1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer[NCT00741260]Phase 1/Phase 2105 participants (Actual)Interventional2008-12-09Completed
A Single-arm Study Evaluating the Relative Dose Intensity of IV CMF Given on Day 1 and Day 8 With Pegfilgrastim Support in Subjects With Stage I-III Breast Cancer[NCT00124111]Phase 20 participants InterventionalCompleted
A Single Arm Open-label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-line Treatment of Patients With HER2-positive Locally Recurrent or Metastatic Breast Cancer[NCT00811135]Phase 288 participants (Actual)Interventional2008-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Benefit Rate

The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.

Interventionpercentage of participants (Number)
Prior Lapatinib Subjects71.4
Lapatinib Naive Subjects P172.1
Lapatinib Naive Subjects Part 2 + Part 173.0

Duration of Response

Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00741260)
Timeframe: From start date of response to first PD/death, up to three years.

Interventionweeks (Median)
Prior Lapatinib Subjects48.3
Lapatinib Naive Subjects P146.3
Lapatinib Naive Subjects Part 2 + Part 146.3

Maximum Tolerated Dose (MTD) of Capecitabine

MTD reflects the highest dose of capecitabine in combination with neratinib that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.

Interventionmg/m^2 (Number)
Capecitabine in Combination With Neratinib1500

Maximum Tolerated Dose (MTD) of Neratinib

MTD reflects the highest dose of neratinib plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.

Interventionmg (Number)
Neratinib in Combination With Capecitabine240

Number of Participants With Dose Limiting Toxicities

Number of participants reporting Adverse Events Causing Dose Limiting Toxicities (DLT). (NCT00741260)
Timeframe: From first dose date to day 21

InterventionParticipants (Count of Participants)
N160 + C15000
N160 + C20002
N200 + C20002
N240 + C15000
N240 + C20002
N + C MTD - No Prior Lap0
N + C MTD - Prior Lap0

Overall Response Rate

Number of Subjects with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.

Interventionpercentage of participants (Number)
Prior Lapatinib Subjects57.1
Lapatinib Naive Subjects P163.9
Lapatinib Naive Subjects Part 2 + Part 163.5

Duration of Response (DR)

DR was defined as the time from the first recorded response (CR/PR) to the date of first documented progression or death. CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionmonths (Median)
Trastuzumab + Bevacizumab + Capecitabine12.7

Number of Participants With Disease Progression or Death

Disease progression was defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionparticipants (Number)
Trastuzumab + Bevacizumab + Capecitabine70

Number of Participants With Overall Survival (OS)

OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionparticipants (Number)
Trastuzumab + Bevacizumab + Capecitabine40

Number of Participants With Response

Participants who had CR or PR were considered as responders. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionparticipants (Number)
Trastuzumab + Bevacizumab + Capecitabine66

Number of Participants With Time to Progression (TTP)

TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). TTP was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionparticipants (Number)
Trastuzumab + Bevacizumab + Capecitabine62

Overall Survival (OS)

OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. OS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionmonths (Median)
Trastuzumab + Bevacizumab + Capecitabine31.8

Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)

Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.0. BOR was defined as the best response recorded for a participant from the start of treatment until disease progression/recurrence. Percentage of participants with a BOR of confirmed CR or PR (responders) was reported. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Confirmed responses were those which were confirmed by a repeat assessment, performed 4 weeks after the criteria for response first met. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionpercentage of participants (Number)
Trastuzumab + Bevacizumab + Capecitabine75.0

Progression Free Survival (PFS)

PFS was defined as the time from enrollment to time of first documented disease progression or death due to any cause, whichever occurred first. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionmonths (Median)
Trastuzumab + Bevacizumab + Capecitabine14.2

Time to Progression (TTP)

TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Interventionmonths (Median)
Trastuzumab + Bevacizumab + Capecitabine14.5

Reviews

2 reviews available for fluorouracil and Breast Cancer, Male

ArticleYear
Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Breast cancer research and treatment, 2012, Volume: 136, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms,

2012
[Clinical research advancement on male breast cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:10

    Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis

2007

Trials

12 trials available for fluorouracil and Breast Cancer, Male

ArticleYear
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-10, Volume: 32, Issue:32

    Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot

2014
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
    International journal of cardiology, 2011, Apr-14, Volume: 148, Issue:2

    Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

2011
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal

2009
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms,

2010
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
    The oncologist, 2012, Volume: 17, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study.
    Cytokine, 1995, Volume: 7, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Dos

1995
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal

1996
Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.
    Breast cancer research and treatment, 1997, Volume: 45, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1997
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia.
    Anti-cancer drugs, 1999, Volume: 10, Issue:4

    Topics: Administration, Topical; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Brea

1999
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:8

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al

1999
FILM (5-fluorouracil, ifosfamide, leucovorin and mitomycin C), an alternative chemotherapy regimen suitable for the treatment of advanced breast cancer in the 'out-patient' setting.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44 Suppl

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Brea

1999
A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma.
    American journal of clinical oncology, 2000, Volume: 23, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car

2000

Other Studies

29 other studies available for fluorouracil and Breast Cancer, Male

ArticleYear
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Breast cancer research and treatment, 2019, Volume: 175, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms,

2019
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
    Journal of UOEH, 2019, Volume: 41, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined M

2019
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
    Breast cancer research and treatment, 2013, Volume: 141, Issue:1

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inh

2013
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.
    The International journal of biological markers, 2013, Dec-17, Volume: 28, Issue:4

    Topics: Adult; Aged; Angiotensinogen; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast

2013
Failure and success in the treatment of breast carcinoma in men: a case report.
    Polish orthopedics and traumatology, 2014, Jan-03, Volume: 79

    Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Breast Neoplasms, Male; Carcinoma, Ductal

2014
[Adenoid cystic carcinoma of the breast:report of 25 cases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl

2014
Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2014
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
    Clinical breast cancer, 2010, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Ma

2010
The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a Nigerian semiurban teaching hospital: a single-center descriptive study.
    World journal of surgery, 2010, Volume: 34, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Br

2010
Invited commentary: The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a nigerian semiurban teaching hospital: a single-center descriptive study.
    World journal of surgery, 2010, Volume: 34, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Br

2010
The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
    Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:2

    Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

2011
Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients.
    Surgery today, 2011, Volume: 41, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal

2011
Mandibular metastases as first clinical sign of an occult male breast cancer.
    International journal of oral and maxillofacial surgery, 2012, Volume: 41, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Bre

2012
[Male breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Combined Modality Ther

2003
[Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc

2005
Inflammatory breast cancer in a male.
    The New Zealand medical journal, 2005, Jul-15, Volume: 118, Issue:1218

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cyclophospha

2005
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breas

2006
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up.
    Breast cancer research and treatment, 2007, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Chemotherapy, A

2007
Multiple cutaneous metastases from male breast carcinoma.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; C

2006
Male breast cancer with mandibular metastasis. A case report.
    Minerva stomatologica, 2007, Volume: 56, Issue:4

    Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplast

2007
[Postoperative radiotherapy of the chest wall in patients with male breast cancer].
    Zentralblatt fur Chirurgie, 2007, Volume: 132, Issue:5

    Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Ch

2007
[Systemic therapy of male breast cancer].
    Zentralblatt fur Chirurgie, 2007, Volume: 132, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antine

2007
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
    Journal of cutaneous pathology, 2007, Volume: 34, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi

2007
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
    Nihon geka hokan. Archiv fur japanische Chirurgie, 1995, Jan-01, Volume: 64, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcin

1995
5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients.
    Cancer research, 1997, Jul-01, Volume: 57, Issue:13

    Topics: Adipose Tissue; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neop

1997
Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer.
    Acta oncologica (Stockholm, Sweden), 1997, Volume: 36, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine

1997
Four years experience of primary intra-arterial chemotherapy (PIAC) for locally advanced and recurrent breast cancer.
    Minerva chirurgica, 1997, Volume: 52, Issue:9

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast

1997
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
    Surgery today, 2001, Volume: 31, Issue:2

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Car

2001
[Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cisp

2001